Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
10.99
-0.04 (-0.36%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
23.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Jasper Therapeutics | 22 |
| Atossa Therapeutics | 16 |
| Actuate Therapeutics | 12 |
| Tvardi Therapeutics | 12 |
| Psyence Biomedical | 12 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 10 |
PLRZ News
- 1 day ago - Polyrizon files to sell 404,166 ordinary shares for holders - TheFly
- 15 days ago - Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement - GlobeNewsWire
- 16 days ago - Polyrizon announces $4.0M registered direct offering - TheFly
- 16 days ago - Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement - GlobeNewsWire
- 17 days ago - Polyrizon completes all five U.S. site contracts for Nasarix allergy study - TheFly
- 17 days ago - Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study - GlobeNewsWire
- 4 weeks ago - Polyrizon completes clinical site network for NASARIX study - TheFly
- 4 weeks ago - Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment - GlobeNewsWire